Translate Bio (Translate Bio) Price-to-Tangible-Book : 8.89 (As of Apr. 26, 2024)

View and export this data going back to 2018. Start your Free Trial

What is Translate Bio Price-to-Tangible-Book?

As of today (2024-04-26), Translate Bio's share price is $37.36. Translate Bio's Tangible Book per Share of Jun. 2021 for the quarter that ended in Jun. 2021 was $4.20. Hence, Translate Bio's Price to Tangible Book Ratio of today is 8.89.

The historical rank and industry rank for Translate Bio's Price-to-Tangible-Book or its related term are showing as below:

TBIO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.84 Med: 7.37 Max: 370.37
Current: 8.9

During the past 5 years, Translate Bio's highest Price to Tangible Book Ratio was 370.37. The lowest was 3.84. And the median was 7.37.

TBIO's Price-to-Tangible-Book is not ranked
in the Biotechnology industry.
Industry Median: 2.67 vs TBIO: 8.90

A closely related ratio is called PB Ratio. As of today, Translate Bio's share price is $37.36. Translate Bio's Book Value per Sharefor the quarter that ended in Jun. 2021 was $5.48. Hence, Translate Bio's P/B Ratio of today is 6.82.

Translate Bio Price-to-Tangible-Book Historical Data

The historical data trend for Translate Bio's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Translate Bio Price-to-Tangible-Book Chart

Translate Bio Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Price-to-Tangible-Book

10.48

5.40

Translate Bio Quarterly Data
	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21
Price-to-Tangible-Book	Get a 7-Day Free Trial														7.37	3.84	5.40	4.27	6.55

Competitive Comparison of Translate Bio's Price-to-Tangible-Book

For the Biotechnology subindustry, Translate Bio's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Translate Bio's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Translate Bio's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Translate Bio's Price-to-Tangible-Book falls into.

Translate Bio Price-to-Tangible-Book Calculation

Translate Bio's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2021 )
	=	37.36	/	4.204
	=	8.89

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Translate Bio Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Translate Bio's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Translate Bio (Translate Bio) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Translate Bio Inc (NAS:TBIO) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

N/A

Address

29 Hartwell Avenue, Lexington, MA, USA, 02421

Website

http://www.translate.bio

Translate Bio Inc is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. The company is developing MRT5005, for the treatment of cystic fibrosis (CF) and MRT5201, for the treatment of ornithine transcarbamylase (OTC) deficiency.

Executives

Jean Francois Formela	director	C/O ATLAS VENTURE, 890 WINTER STREET, WALTHAM MA 02451
Renaud Ronald C Jr	director, officer: Chief Executive Officer, other: President	C/O IDENIX PHARMACEUTICALS, INC., 60 HAMPSHIRE STREET, CAMBRIDGE MA 02109
Paul D. Burgess	officer: Chief Operating Officer, CLO, other: Secretary	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Owen Hughes	director	C/O RADIUS HEALTH, INC., 201 BROADWAY, 6TH FLOOR, BOSTON MA 02139
Shire Human Genetic Therapies, Inc.	10 percent owner	300 SHIRE WAY LEXINGTON MA 02421
Takeda Pharmaceutical Co Ltd	10 percent owner	1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU, TOKYO M0 103-8668
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Baupost Group Llc/ma	10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Daniella Beckman	director	C/O IDENIX PHARMACEUTICALS, INC., ONE KENDALL SQUARE, BLDG. 1400, CAMBRIDGE MA 02139
Robert M Plenge	director	C/O TRANSLATE BIO, INC., 29 HARTWELL AVENUE, LEXINGTON MA 02421
Daniel Lynch	director
Robert J. Meyer	director	2505 MERIDIAN PARKWAY, C/O CHIMERIX, INC, SUITE 100, DURHAM NC 27713
Ann Barbier	officer: Chief Medical Officer	255 STATE STREET, C/O PIERIS PHARMACEUTICALS,INC., BOSTON MA 02109